MK-4280
Biological
Merck Sharp & Dohme Corporation
Total Payments
$13.8M
Transactions
4,808
Doctors
10
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5.2M | 1,509 | 4 |
| 2019 | $4.4M | 2,589 | 6 |
| 2018 | $2.9M | 434 | 4 |
| 2017 | $1.3M | 276 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.7M | 4,747 | 98.7% |
| Consulting Fee | $169,493 | 44 | 1.2% |
| Travel and Lodging | $16,821 | 9 | 0.1% |
| Food and Beverage | $323.69 | 8 | 0.0% |
Payments by Type
Research
$13.7M
4,747 transactions
General
$186,638
61 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab inSubjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $4.1M | 0 |
| A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chomotherapy in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $3.7M | 0 |
| A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib E7080,MK-7902 in Subjects with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $3.2M | 0 |
| A Phase 1,Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab MK-3475 in Participants with Hematologic Malignancies | Merck Sharp & Dohme Corporation | $2.6M | 0 |
| A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies | Merck Sharp & Dohme Corporation | $32,492 | 0 |
| A Phase 3 study of Pembrolizumab MK-3475 plus MK-4280 Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer | Merck Sharp & Dohme Corporation | $400.00 | 0 |
Top Doctors Receiving Payments for MK-4280
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $13.7M | 4,747 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $57,390 | 12 |
| , MD | Diagnostic Radiology | New Hyde Park, NY | $50,998 | 8 |
| , MD | Diagnostic Radiology | Tampa, FL | $35,220 | 7 |
| , M.D | Diagnostic Radiology | Boca Raton, FL | $24,185 | 14 |
| , M.D., M.S., F.A.C.P | Internal Medicine | Gilbert, AZ | $10,604 | 7 |
| , MD | Hematology & Oncology | Gilbert, AZ | $6,453 | 8 |
| , M.D | Pediatric Hematology-Oncology | Seattle, WA | $1,000 | 1 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $700.00 | 2 |
| , MD | Hematology & Oncology | Nashville, TN | $43.95 | 1 |
| , M.D | Hematology & Oncology | Grand Rapids, MI | $43.95 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $13.8M
- Total Doctors 10
- Transactions 4,808
About MK-4280
MK-4280 is a biological associated with $13.8M in payments to 10 healthcare providers, recorded across 4,808 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $5.2M was paid across 1,509 transactions to 4 doctors.
The most common payment nature for MK-4280 is "Unspecified" ($13.7M, 98.7% of total).
MK-4280 is associated with 6 research studies, including "A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab inSubjects with Advanced Solid Tumors" ($4.1M).